The Role of Glucagon-Like Peptide-1 in Energy Homeostasis

被引:23
|
作者
Salehi, Marzieh [1 ,2 ]
Purnell, Jonathan Q. [3 ]
机构
[1] Univ Texas Hlth San Antonio, Dept Internal Med, Div Diabet, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA
[2] South Texas Veteran Hlth Care Syst, Audie Murphy Hosp, Bartter Res Unit, San Antonio, TX USA
[3] Oregon Hlth & Sci Univ, Mailcode MDYMI, Knight Cardiovasc Inst, Portland, OR 97201 USA
关键词
appetite; energy homeostasis; glucagon-like peptide-1 (GLP-1); gut-brain axis; GLP-1 ANALOG LIRAGLUTIDE; Y GASTRIC BYPASS; LAPAROSCOPIC SLEEVE GASTRECTOMY; GUT-BRAIN AXIS; BARIATRIC SURGERY; ENDOGENOUS GLP-1; FOOD-INTAKE; SUBSTRATE METABOLISM; GLUCOSE-METABOLISM; RECEPTOR AGONISTS;
D O I
10.1089/met.2018.0088
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Energy homeostasis is coordinated by bidirectional communication pathways between the brain and peripheral organs, including adipose tissue, muscle, the pancreas, liver, and gut. Disruption of the integrated chemical, hormonal, and neuronal signals that constitute the gut-brain axis significantly contributes to disorders of metabolism and body weight. Initial studies of glucagon-like peptide-1 (GLP-1), a gut hormone released in response to the ingestion of nutrients, focused on its incretin actions to improve postprandial glucose homeostasis by enhancing meal-induced insulin secretion. However, GLP-1 is also a key player in the gut-brain regulatory axis with multiple effects on appetite and energy metabolism outside of its peripheral glucoregulatory actions. In this review, we explore the function of GLP-1 as a component of the gut-brain axis in the regulation of energy homeostasis, and consider the implications of this role for the development of therapeutic treatment options for obesity.
引用
收藏
页码:183 / 191
页数:9
相关论文
共 50 条
  • [31] A role for Glucagon-Like Peptide-1 in the regulation of β-cell autophagy
    Arden, Catherine
    PEPTIDES, 2018, 100 : 85 - 93
  • [32] Ghrelin and glucagon-like peptide-1 according to body adiposity and glucose homeostasis
    Lopes, Karynne Grutter
    da Silva Junior, Vicente Lopes
    Marques Lopes, Fernanda de Azevedo
    Bouskela, Eliete
    Coelho de Souza, Maria das Gracas
    Kraemer-Aguiar, Luiz Guilherme
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2023, 67 (04):
  • [33] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [34] Glucagon-Like Peptide-1 Receptor Agonists
    Edelman, Steven V.
    JOURNAL OF FAMILY PRACTICE, 2017, 66 (10): : S12 - S16
  • [35] Glucagon-like peptide-1, a matter of taste?
    Jensterle, Mojca
    DeVries, J. Hans
    Battelino, Tadej
    Battelino, Saba
    Yildiz, Bulent
    Janez, Andrej
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2021, 22 (04): : 763 - 775
  • [36] Glucagon-Like Peptide-1 Gene Therapy
    Rowzee, Anne M.
    Cawley, Niamh X.
    Chiorini, John A.
    Di Pasquale, Giovanni
    EXPERIMENTAL DIABETES RESEARCH, 2011,
  • [37] Is ghrelin a glucagon-like peptide-1 secretagogue?
    Ueno, Hiroaki
    Nakazato, Masamitsu
    JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (04) : 466 - 467
  • [38] Glucagon-like peptide-1 and safety - Reply
    Bloom, SR
    NATURE, 1997, 385 (6613) : 214 - 214
  • [39] Glucagon-Like Peptide-1 and Diabetes 2012
    Monami, Matteo
    Di Pasquale, Giovanni
    Rowzee, Anna
    Rotella, Carlo Maria
    Mannucci, Edoardo
    EXPERIMENTAL DIABETES RESEARCH, 2012,
  • [40] Glucagon-like peptide-1 and islet lipolysis
    Winzell, MS
    Ahrén, B
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 795 - 803